BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOMARIN PHARMACEUTICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$54.67−0.01 (-0.02%)
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
BIOMARIN PHARMACEUTICAL INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $3.17B | $2.81B | $2.37B | $2.04B | $1.78B | $1.81B | $1.66B | $1.47B | $1.27B | $1.11B | 98.3% | +12.8% |
| VOXZOGO | $926.92M | $735.09M | $469.88M | $169.13M | $5.86M | – | – | – | – | – | 28.8% | +26.1% |
| VIMIZIM | $792.05M | $739.78M | $701.05M | $663.74M | $623.15M | – | – | – | – | – | 24.6% | +7.1% |
| NAGLAZYME | $485.40M | $479.58M | $420.29M | $443.79M | $380.45M | – | – | – | – | – | 15.1% | +1.2% |
| PALYNZIQ | $433.31M | $355.05M | $303.92M | $255.03M | $237.47M | – | – | – | – | – | 13.5% | +22.0% |
| ALDURAZYME | $208.51M | $183.89M | $131.25M | $128.42M | $122.77M | – | – | – | – | – | 6.5% | +13.4% |
| BRINEURA | $186.40M | $169.08M | $161.89M | $154.33M | $128.03M | – | – | – | – | – | 5.8% | +10.2% |
| KUVAN | $99.53M | $120.90M | $180.77M | $227.58M | $285.78M | – | – | – | – | – | 3.1% | -17.7% |
| Royalty and other revenues | $53.49M | $44.47M | $46.69M | $54.01M | $62.78M | $54.59M | $43.01M | $20.86M | $43.20M | $6.47M | 1.7% | +20.3% |
| ROCTAVIAN | $35.64M | $26.07M | $3.49M | $0 | $0 | – | – | – | – | – | 1.1% | +36.7% |
| KUVAN | – | – | – | – | – | – | $22.35M | $21.79M | $18.89M | $18.03M | – | – |
| VIMIZIM | – | – | – | – | – | – | $374.33M | $345.85M | $332.21M | $296.54M | – | – |
| NAGLAZYME | – | – | – | – | – | – | $463.35M | $433.58M | $407.54M | $348.01M | – | – |
| VOXZOGO | – | – | – | – | – | – | $72.00M | $39.89M | $8.60M | $0 | – | – |
| ALDURAZYME net product revenues marketed by Sanofi | – | – | – | – | – | – | $97.81M | $135.10M | $89.96M | $93.75M | – | – |
| PALYNZIQ | – | – | – | – | – | – | $544.35M | $481.98M | $413.25M | $354.06M | – | – |
| BRINEURA | – | – | – | – | – | – | $86.86M | $12.17M | $0 | $0 | – | – |
| Total enzyme product revenues | – | – | $1.72B | $1.65B | $1.49B | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | $912.38M | $778.44M | $696.79M | $588.24M | $507.54M | – | – |
| Europe | – | – | – | – | – | $518.47M | $509.19M | $436.43M | $398.81M | $340.78M | – | – |
| Latin America | – | – | – | – | – | $205.86M | $218.79M | $185.05M | $181.97M | $147.47M | – | – |
| Rest of world | – | – | – | – | – | $223.75M | $197.63M | $172.94M | $144.62M | $121.07M | – | – |
From the segment and revenue-disaggregation notes of Biomarin Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.